University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 11 of 12
Examining the Link Between Depression and Seasonal Allergies
NCT00770068
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
NCT00799396
A Safe Environment for Every Kid (SEEK): A Model for Primary Care
NCT00819702
Toddler Overweight Prevention Study Among Low-Income Families
NCT02615158
Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer
NCT00321958
Assessment of Coronary Artery Disease by Hybrid PET/CT
NCT00320931
Strengthening Family Coping Resources Open Trials
NCT01754610
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
NCT00344487
Renal Effects of Intrarenal Nesiritide
NCT00270829
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
NCT00257738
Aging, Lifestyle and Inflammation in Veterans Exercising
NCT00667030
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
NCT00261807
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
NCT00295139
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
NCT00344760
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
NCT00343083
Cognitive Remediation for Schizophrenia
NCT00295048
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
NCT00161044
Improving Cardiovascular Treatment Approaches Among Minorities
NCT00101478
Familial Schizophrenia and Spectrum Personality Disorders
NCT00666146
Early Childhood Caries Prevention at a Pediatric Clinic
NCT00497029
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
NCT00161031
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
NCT00344461
Alcohol Use Disorders in Schizophrenia
NCT00280813
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00176436
Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression
NCT00336778
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
NCT00161018
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
NCT00390182
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
NCT00344981
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00049374
Electrophysiological Effects of Late PCI After MI
NCT00119847
A Safe Environment for Every Kid (SEEK) I
NCT00507299
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176423
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
NCT00046852
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00056498
Effect of Chronic Changes in Heart Rate on Congestive Heart Failure
NCT00389649
Clinical Trial of Dipyridamole in Schizophrenia
NCT00349973
A Comparison of Bupropion SR and Placebo for Smoking Cessation
NCT00176449
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
NCT00015951
Challenge!, a Health Promotion/ Obesity Prevention Program for Teens
NCT00746083
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
NCT00014183
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
NCT00005946
BHS5 - Testing the Effectiveness of the Exercise Plus Program
NCT00389844
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
NCT00005028
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
NCT00005858
Hepatitis B Vaccine in Seniors
NCT04162223
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00006350
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
NCT00222235
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
NCT00004009
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00003727
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00003402
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.